{"id":379018,"date":"2020-11-11T16:18:16","date_gmt":"2020-11-11T21:18:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=379018"},"modified":"2020-11-11T16:18:16","modified_gmt":"2020-11-11T21:18:16","slug":"lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/","title":{"rendered":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Webcast will not include results from any Phase 3 clinical trials<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">INDIANAPOLIS<\/span>, <span class=\"xn-chron\">Nov. 11, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Eli Lilly and Company (NYSE: LLY) will conduct a webcast on <span class=\"xn-chron\">Friday, November 20, 2020<\/span> to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at <span class=\"xn-chron\">11:00 a.m. Eastern Standard Time<\/span> and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program. <\/p>\n<p>Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979100-1&amp;h=504780904&amp;u=https%3A%2F%2Finvestor.lilly.com%2Fwebcasts-and-presentations&amp;a=https%3A%2F%2Finvestor.lilly.com%2Fwebcasts-and-presentations\" rel=\"nofollow noopener noreferrer\">https:\/\/investor.lilly.com\/webcasts-and-presentations<\/a>. A replay will also be available on the website following the conference call.<\/p>\n<p>\n        <b>About\u00a0Eli Lilly and Company<br \/><\/b>Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2979100-1&amp;h=36288082&amp;u=http%3A%2F%2Fwww.lilly.com%2F&amp;a=www.lilly.com\" rel=\"nofollow noopener noreferrer\">www.lilly.com<\/a>. \u00a0F-LLY\u00a0\u00a0\u00a0 <\/p>\n<p>\n        <b><br \/>\n          <i><br \/>\n            <u>Lilly Cautionary Statement Regarding Forward-Looking Statements <br \/><\/u><br \/>\n          <\/i><br \/>\n        <\/b><br \/>\n        <i>This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about tirzepatide and reflects Lilly&#8217;s current beliefs.\u00a0 However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of research and development. For a further discussion of these and other risks and uncertainties, please see Lilly&#8217;s most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.<\/i>\n      <\/p>\n<p>\n        <b>Refer to:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Mark Taylor<\/span>; <a target=\"_blank\" href=\"mailto:mark.taylor@lilly.com\" rel=\"nofollow noopener noreferrer\">mark.taylor@lilly.com<\/a>; (317) 276-5795 (Media)\u00a0\u00a0\u00a0<br \/><span class=\"xn-person\">Kevin Hern<\/span>; <a target=\"_blank\" href=\"mailto:hern_kevin_r@lilly.com\" rel=\"nofollow noopener noreferrer\">hern_kevin_r@lilly.com<\/a>;\u00a0(317) 277-1838 (Investors)<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1335\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg\" title=\"Eli Lilly and Company logo. (PRNewsfoto\/Eli Lilly and Company)\" alt=\"Eli Lilly and Company logo. (PRNewsfoto\/Eli Lilly and Company)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder0\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=DE88975&amp;sd=2020-11-11\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program-301171326.html\">http:\/\/www.prnewswire.com\/news-releases\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program-301171326.html<\/a><\/p>\n<p>SOURCE  Eli Lilly and Company<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=DE88975&amp;Transmission_Id=202011111615PR_NEWS_USPR_____DE88975&amp;DateId=20201111\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Webcast will not include results from any Phase 3 clinical trials PR Newswire INDIANAPOLIS, Nov. 11, 2020 \/PRNewswire\/ &#8212;\u00a0Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at 11:00 a.m. Eastern Standard Time and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly&#8217;s website at https:\/\/investor.lilly.com\/webcasts-and-presentations. A replay will also be available on the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-379018","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Webcast will not include results from any Phase 3 clinical trials PR Newswire INDIANAPOLIS, Nov. 11, 2020 \/PRNewswire\/ &#8212;\u00a0Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at 11:00 a.m. Eastern Standard Time and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly&#8217;s website at https:\/\/investor.lilly.com\/webcasts-and-presentations. A replay will also be available on the &hellip; Continue reading &quot;Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-11T21:18:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program\",\"datePublished\":\"2020-11-11T21:18:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/\"},\"wordCount\":381,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/458388\\\/Eli_Lilly_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/\",\"name\":\"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/458388\\\/Eli_Lilly_Logo.jpg\",\"datePublished\":\"2020-11-11T21:18:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/458388\\\/Eli_Lilly_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/458388\\\/Eli_Lilly_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/","og_locale":"en_US","og_type":"article","og_title":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk","og_description":"Webcast will not include results from any Phase 3 clinical trials PR Newswire INDIANAPOLIS, Nov. 11, 2020 \/PRNewswire\/ &#8212;\u00a0Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Friday, November 20, 2020 to provide an overview of the tirzepatide Phase 3 type 2 diabetes clinical trial program in preparation for five future Phase 3 top-line data disclosures. The webcast will begin at 11:00 a.m. Eastern Standard Time and will review the trial designs and expected timing of the multiple readouts for the tirzepatide program. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly&#8217;s website at https:\/\/investor.lilly.com\/webcasts-and-presentations. A replay will also be available on the &hellip; Continue reading \"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-11T21:18:16+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program","datePublished":"2020-11-11T21:18:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/"},"wordCount":381,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/","name":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg","datePublished":"2020-11-11T21:18:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/458388\/Eli_Lilly_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lilly-announces-webcast-to-provide-an-overview-of-tirzepatide-phase-3-clinical-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lilly Announces Webcast to Provide an Overview of Tirzepatide Phase 3 clinical program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379018","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=379018"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/379018\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=379018"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=379018"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=379018"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}